Systemic inflammatory response syndrome criteria in defining severe sepsis

New England Journal of Medicine

Volumn 372, Issue 17, 2015, Pages 1629-1638

  Kaukonen, Kirsi Maija ^a,e   Bailey, Michael ^a   Pilcher, David ^a,b,c   Cooper, D Jamie ^a   Bellomo, Rinaldo ^a,d  

^a MONASH UNIVERSITY   (Australia)

^b Australian and New Zealand Intensive Care Society   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d AUSTIN HEALTH   (Australia)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; CONSTRUCT VALIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FACE VALIDITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; NEW ZEALAND; OUTCOME ASSESSMENT; PATIENT CODING; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; CLASSIFICATION; FACTUAL DATABASE; MIDDLE AGED; ORGAN DYSFUNCTION SCORE; RETROSPECTIVE STUDY; RISK; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

AGED; AUSTRALIA; DATABASES, FACTUAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NEW ZEALAND; ODDS RATIO; ORGAN DYSFUNCTION SCORES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEPSIS; SEVERITY OF ILLNESS INDEX; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84928485055     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1415236     Document Type: Article

References (26)

1. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013;41:1167-74.
2. Brun-Buisson C, Meshaka P, Pinton P, Vallet B. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30:580-8.
3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
4. Opal SM, Laterre P-F, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013;309:1154-62.
5. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-64.
6. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012;367:124-34. [Erratum, N Engl J Med 2012;367:481.]
7. Annane D, Cariou A, Maxime V, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010;303:341-8. [Erratum, JAMA 2010;303:1698.]
8. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
9. Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015;372:1301-11.
10. The ARISE Investigators and the ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014;371:1496-506.
11. Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin thresh-old for transfusion in septic shock. N Engl J Med 2014;371:1381-91.
12. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. . . . Crit Care Med 1997;25:372-4.
13. Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet 2013;381:774-5.
14. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003;29:530-8.
15. Sprung CL, Sakr Y, Vincent JL, et al. An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely Ill Patients (SOAP) study. Intensive Care Med 2006;32: 421-7.
16. Stow PJ, Hart GK, Higlett T, et al. Development and implementation of a highquality clinical database: the Australian and New Zealand Intensive Care Society Adult Patient Database. J Crit Care 2006;21:133-41.
17. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
18. Karlsson S, Varpula M, Ruokonen E, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 2007;33:435-43.
19. Paul E, Bailey M, Pilcher D. Risk prediction of hospital mortality for adult patients admitted to Australian and New Zealand intensive care units: development and validation of the Australian and New Zealand Risk of Death model. J Crit Care 2013;28:935-41.
20. Pilcher D, Paul E, Bailey M, Huckson S. The Australian and New Zealand Risk of Death (ANZROD) model: getting mortality prediction right for intensive care units. Crit Care Resusc 2014;16:3-4.
21. Paul E, Bailey M, van Lint A, Pilcher V. Performance of APACHE III over time in Australia and New Zealand: a retrospective cohort study. Anaesth Intensive Care 2012;40:980-94.
22. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995;273:117-23.
23. Alberti C, Brun-Buisson C, Chevret S, et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med 2005;171:461-8.
24. Liao MM, Lezotte D, Lowenstein SR, et al. Sensitivity of systemic inflammatory response syndrome for critical illness among ED patients. Am J Emerg Med 2014;32:1319-25.
25. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-16.
26. Improving global outcomes (KDIGO): clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1-138.